Global Medulloblastoma Drug Market – Industry Trends and Forecast to 2029

Medulloblastoma Drug Market Analysis and Size

The medulloblastoma drug market is expected to witness significant growth during the forecast period. The growing occurrence of brain tumors is projected to increase the growth of the market during the forecast period. Increased incidence of brain tumor & another type of cancer globally will boost up the global medulloblastoma drug market. But, exact causes behind the occurrence of brain tumor and late symptoms of the cancer may impede the global medulloblastoma drug market. COVID-19 also had a major impact on the market growth.

Data Bridge Market Research analyses a growth rate in the global medulloblastoma drug market in the forecast period 2022-2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Medulloblastoma Drug Market Scope and Segmentation

Market Definition

Medulloblastoma is a type of brain tumor that occurs in the lower back part of the brain, called the cerebellum. The cerebellum helps in muscle coordination, balance and movement. Medulloblastoma is an embryonal tumor that initiates in the embryonic cells in the brain. The patient suffers from headaches, nausea, tiredness, dizziness, double vision, vomiting, and poor coordination; this condition also develops unsteady walk and pressure build up in the brain. The tumor rarely spreads to other areas of the body.

Global Medulloblastoma Drug Market Dynamics

Drivers

• Growing Surgeries and Reimbursement Policies

The presence of reimbursement policies that boost healthcare professionals to maintain quality infrastructure is estimated to increase the demand for surgery in this market. Thus, more and more success rate of surgeries and reimbursement policies is surely expected to increase the market growth. In addition, the number of surgical procedures for treating glioma in emerging economies, including China and India, is growing. Governments of China and India have improved their healthcare spend, which in turn is augmenting the admission of patients in hospitals.

• Rising Demand for Drugs

There has been several drugs that are helping in increasing the growth of the market. Temozolomide is a drug that is anticipated to treat some types of brain cancer such as  glioblastoma multiforme, anaplastic astrocytoma in individuals who have had tumours return or who have recently been diagnosed with tumours. Thus, it boosts the growth of the market.

Opportunities

• Increased Cases of Brain Tumor

According to the National Brain Tumor Society, about 700,000 people in the U.S. will have primary brain tumor in 2019 and around 86,000 more will be diagnosed. The growing number of patients with neurological disorders, including brain tumor, is leading to a rise in the demand for the drugs used in their treatment.

• Rising Healthcare Awareness

Health awareness amongst the population are rising, resulting in the prediction of drugs to boost market growth. The innovative launches in medications for the treatment of ovarian cancer are expected to prompt the market simultaneously. Different researchers are investing in launching drugs that benefit the market. This creates more opportunities in the market.

Restraints/Challenges

• Increase in Demand of Targeted Therapy

The rising demand for targeted therapy is somewhat hampering the market's growth. Growing use of targeted therapies is acting as a restraint on the medulloblastoma drug market. For instance, Everolimus is a targeted therapy that blocks cancer cells from growing and spreading. Likewise, Bevacizumab prevents the regeneration of cancer cells, unlike chemical drugs that cannot prevent regeneration. This increasing popularity of targeted therapies is projected to affect the sales of conventional chemical Brain tumor drugs, thus limiting the growth of the market during the forecast period.

• Nanotechnology Restricts Sale of Drugs

Market players in the medulloblastoma drug market are focusing on the use of nanotechnology for treatment. The nanoparticles are being used to carry drugs in combination, directly to the cancer cells or into the tumor. This technology has also led to a decline in dosage of the drugs, improved shelf life and decreased toxicity. A few nanodrugs are proving to be useful in overcoming the blood-brain barrier, which was a significant challenge in treating medulloblastoma.

This global medulloblastoma drug market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global medulloblastoma drug market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Medulloblastoma Drug Market

COVID-19 has had a negative impact on the global medulloblastoma drug market. Numerous ICU facilities, such as ventilators, personal protective equipment, and medical staff, were redirected to COVID-19 cases, stimulating the suspension of surgical neuro-oncology services during the COVID-19 pandemic. Instability in the provision of adequate medical care to critically-ill cancer patients was observed during the pandemic. Furthermore, medulloblastoma patients seem to be vulnerable to the COVID-19 infection, which resulted in the postponement of treatments and surgeries. Thus, the market was greatly impacted by the global medulloblastoma drug market.

Global Medulloblastoma Drug Market Scope

The global medulloblastoma drug market is segmented on the basis of drugs, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drugs

• Chemotherapy
• Glucocorticoids
• Osmotic Diuretic
•  Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Homecare
• Speciality Centres
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Medulloblastoma Drug Market Regional Analysis/Insights

The global medulloblastoma drug market is analyzed and market size insights and trends are provided by drusg, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global medulloblastoma drug market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to have the highest market growth due to the presence of key manufacture of the product, high research and development, healthcare expenditure, and skilled professionals.

Asia-Pacific dominates the market due to increased government awareness programs and number of generic drugs.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Medulloblastoma Drug Market Share Analysis

The global medulloblastoma drug market overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global medulloblastoma drug market .

Key players operating in the global medulloblastoma drug market include:

• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd.(Israel)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GSK plc (U.K.)
• Novartis AG (Switzerland)
• Bayer AG (Germany)
• Merck & Co., Inc. (U.S.)
• Abbvie, Inc (U.S.)
• AstraZeneca (U.K.)
• Johnson & Johnson Private Limited (U.S.)
• Abbott (U.S.)
• Bausch Health Companies Inc. (Canada)
• Sun Pharmaceutical Industries Ltd. (India)
• Aurobindo Pharma (India)
• Stemline Therapeutics, Inc (U.S.)
• ONO PHARMACEUTICAL CO., LTD. (Japan)
• KINTARA THERAPEUTICS, INC (U.S.)
• VBI Vaccines Inc (U.S.)

SKU-55300